Immune cell therapy for aggressive meningioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new treatment using special immune cells called gamma-delta T cells, which have been modified to target cancer cells, for people with a type of brain tumor called malignant meningioma that has come back after standard treatments. The goal is to see if this cell therapy can shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 70 years old.
- Diagnosed with a malignant meningioma that has returned after previous treatment.
- Able to walk and care for yourself (ECOG score 0-2).
- At least 4 weeks since your last chemotherapy or targeted therapy.
- Good organ function, including bone marrow, liver, kidneys, and heart.
- Willing to use effective birth control during the study and for 12 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
This trial tests a new treatment using special immune cells called Vγ9Vδ2 T cells, given directly into the brain fluid. It is for people with a very aggressive grade 4 brain tumor (malignant glioma) that has not gotten better with standard treatments.
This trial tests a new immune cell therapy (gamma-delta T cells from a healthy donor) for people with glioblastoma that has come back or gotten worse after standard treatment. It aims to see if these cells can help fight the tumor.
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
This trial tests a vaccine made from immune cells (dendritic cells) designed to train your body to fight brain tumors like DIPG or glioblastoma. You may qualify if you have one of these tumors, have had standard treatment, and are generally healthy enough for the study.
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
Hear when a new Malignant Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.